Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Infigratinib phosphate by QED Therapeutics for Achondroplasia: Likelihood of Approval
Infigratinib phosphate is under clinical development by QED Therapeutics and currently in Phase III for Achondroplasia. According to GlobalData, Phase...